COVID-19 Treatment AND Vaccine Tracker
Last Updated:
September 23, 2020 10:48 AM
Pacific
FasterCures, a center of the Milken Institute, is currently tracking the development of treatments and vaccines for COVID-19 (coronavirus). This tracker contains an aggregation of publicly-available information from validated sources.
Explore detailed information on each development:
Download a .CSV and explore relationships:
Spreadsheet
Understand definitions of the terms and how our researchers distinguish stages of development:
Glossary
See the race for a
vaccine visualized
Drug developers, academic labs, and other organizations globally are developing many different kinds of medical products to treat COVID-19. Treatments give us tools to help patients while a vaccine is developed. Potential treatments include medicines currently used or studied to treat other diseases (“repurposed” treatments), as well as drugs newly identified or designed to treat COVID-19.
Alexion Pharmaceuticals. TACTIC-R trial
Ultomiris (ravulizumab-cwvz), complement inhibitor
clinical
Phase III recruiting July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04369469, EudraCT 2020-001354-22 (TACTIC-R), ISRCTN11188345, NCT04390464
Assistance Publique - Hopitaux de Paris (Phase II); Alexion (Expanded Access Protocols)
Soliris (eculizumab), complement inhibitor
clinical
Phase II recruiting May 2020. Expanded access protocols
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04288713, NCT04346797, NCT04355494, EudraCT 2020-001246-18
AstraZeneca; ACCORD trial
MEDI3506, monoclonal antibody targeting interleukin 33
clinical
ACCORD Phase II trial to start May 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
UK Government (ACCORD study)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Chronic Obstructive Pulmonary Diesase
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
EudraCT 2020-001736-95 (ACCORD Trial)
BioCon/ Equilium
itolizumab, anti-CD6 IgG1 monoclonal antibody
clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Graft versus host disease; Lupus nephritis; Plaque psoriasis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Celltrion
CT-P59; Antibodies from recovered COVID-19 patients
clinical
Phase I trial started July 2020; Celltrion beginning commercial production; Korean Ministry of Food and Drug Safety (MFDS) IND application for a Phase II/III trials Sept 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
The Korea Health Industry Development Institute
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04525079
Celltrion/ University of Oxford/ University Hospitals Birmingham (CATALYST trial)
Remsima (infliximab), anti-TNF antibody
clinical
Phase II trial to start in June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04425538
Cerecor
CERC-002, anti-LIGHT monoclonal antibody
clinical
Phase II recruiting July 2020, top line data expected 4Q 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Pediatric Crohn's Disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04412057
CytoDyn
leronlimab (PRO 140), a CCR5 antagonist
clinical
Phase II trial interim results released July 2020; Phase II trial (mild/moderate) met enrollment in June 2020; Phase IIb/III trial (severe) ongoing June 2020; individual expanded access
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Treatment of HIV/AIDS, Graft versus Host Disease, Non-Alcoholic Steatohepatitis, and numerous cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04343651 NCT04347239
EUSA Pharma / The Papa Giovanni XXII Hospital; University Hospital, Ghent; Fundacion Clinic per a la Recerca Biomédica
Sylvant (siltuximab), interleukin-6 targeted monoclonal
clinical
FDA approves Phase III trial in hospitalized patients in July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04322188, NCT04330638, NCT04329650, EudraCT 2020-001500-41, EudraCT 2020-001854-23, EudraCT 2020-001413-20, NCT04486521
Edesa Biotech/ Light Chain Bioscience (NovImmune)
EB05, non-steroidal anti-inflammatory molecule (sPLA2 inhibitor)
clinical
Phase I/II not yet recruiting July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
ARDS
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04401475
Eli Lilly
LY3127804, anti-Angiopoietin 2 (Ang2) antibody
clinical
Phase II trial recruiting July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04342897
Eli Lilly/ AbCellera (NIH Vaccines Research Center)/Takeda
LY-CoV555 antibody from recovered patients
clinical
Phase III Blaze-2 study enrolling August 2020 at Long-Term care facilities
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Defense Advanced Research Projects Agency/ Government of Canada (ISED Strategic Innovation Fund)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04411628, NCT04427501
GSK
otilimab, anti-granulocyte macrophase colony-stimulating factor (GM-CSF) antibody
clinical
Phase II recruiting June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
To treat rheumatoid arthritis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04376684
Humanigen Inc./ Catalent Biologics
lenzilumab, anti-granulocyte-macrophage colony stimulating factor antibody
clinical
Data on first clinical use released June 2020; Phase III trial ongoing July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Prevent cytokine storm with CAR-T cancer therapy; prevention/treatment of acute graft versus host disease; chronic myelomonocytic leukemia; eosinophilic asthma
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04351152
I-Mab Biopharma
TJM2 (TJ003234), anti-granulocyte-macrophage colony stimulating factor antibody
clinical
Interim Phase I/II data released June 2020, part 2 of the study to start June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04341116
Implicit Bioscience
IC14, recombinant chimeric anti-CD14 monoclonal antibody
clinical
Phase II not yet recruiting July 2020; Expanded access protocols
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Acute Respiratory Distress Syndrome
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04346277, NCT04391309
InflaRx N.V.
IFX-1, anti-C5a antibody
clinical
Phase III trial to begin fall 2020; Phase II topline results reported June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
To treat various inflammatory conditions including hidradenitis suppurativa, ANCA-associated vasculitis, and pyoderma gangraenosum
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04333420, EudraCT 2020-001335-28
Junshi Biosciences/ Eli Lilly/ Lonza
JS016 antibody candidate
clinical
Phase I trial in China started June 2020; trial in US to start 2H 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04441918
Kamada/ Kedrion Biopharma/ Columbia University Irving Medical Center
Antibodies from recovered COVID-19 patients
clinical
Individual Expanded Access use in Israel started in June 2020; Phase I/II in hospitalized patients in Israel to start 3Q 2020; Will talk to FDA in 3Q 2020; enrollment completed Sept 2020 in Israel
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Kiniksa/ Cleveland Clinic/ Ospedale San Raffaele
mavrilimumab, anti-granulocyte-macrophase colony-stimunlating factor receptor-alpha monoclonal antibody
clinical
Phase II trial recruiting June 2020; Case reports published June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Giant cell arteritis (GCA); rheumatoid arthritis; large B-cell lymphoma (with Yescarta)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04399980, NCT04397497, NCT04447469, NCT04463004
Multiple global research sponsors, including: New York State Department of Health; Johns Hopkins University; the Feinstein Institutes; RECOVERY trial
Convalescent plasma (blood plasma from recovered patients)
clinical
Mayo Clinic and Houston Methodist trial results published June 2020, other trials ongoing; FDA issued Emergency Use Authorization on Aug 23, 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Bloomberg Philantropies and the State of Maryland (to Johns Hopkins University)/ Biomedical Advanced Research and Development Authority (BARDA) (to Mayo Clinic), Department of Defense (DoD)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Many expanded access, observational, patient registry, plasma collection, prevention, and other studies listed in clinicaltrials.gov, including: NCT04321421, NCT04292340, NCT04316728, NCT04338360, NCT04345289, NCT04349410, NCT04346589, NCT04333251, NCT04361253, NCT04323800, NCT04359810, NCT04362176, NCT04354831, NCT04360486, NCT04321421, NCT04441424, NCT04460547, NCT04381936 (RECOVERY), EudraCT 2020-001310-38, ISRCTN67000769 (REMAP-CAP), EudraCT 2015-002340-14 (REMAP-CAP), NCT02735707 (MJM Bonten), NCT04467151, NCT04442191, NCT04456413, NCT04438057, NCT04377568, NCT04418518, NCT04408040, NCT04397757, NCT04390503, NCT04385199, NCT04421404, NCT04364737, NCT04344535, NCT04355767, NCT04373460, NCT04377672, NCT04528368, NCT04497324
Multiple global research sponsors; Octapharma USA/ Sharp Memorial Hospital; Grifols
Octagam; intravenous Immunoglobulin (IVIG)
clinical
Octapharma released topline results from retrospective study July 2020; Phase III study ongoing July 2020; Phase 1/2 trials began
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04261426, NCT04264858, NCT04350580, NCT04400058, NCT04411667, EudraCT 2020-002482-34, NCT04480424, NCT04432324, 2020-001890-56, NCT04521309
Novartis; other research sponsors
Ilaris (canakinumab), interleukin-1beta blocker
clinical
Novartis Phase III to start and trial top-line results expected late summer 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04348448, NCT04362813, NCT04365153, EudraCT 2020-001854-23, NCT04476706
Numerous trials with Chinese research sponsors
PD-1 blocking antibody; Thymosin
clinical
Phase II study not yet recruiting
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04268537, ChiCTR2000030028
Numerous trials with Chinese research sponsors; Roche
Avastin (bevacizumab), vascular endothelial growth factor inhibitor
clinical
Phase II/III studies recruiting April 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04275414, NCT04305106, NCT04344782, EudraCT 2020-001246-18
Numerous trials with global research sponsors; Roche; REMAP-CAP; RECOVERY
Actemra (tocilizumab), interleukin-6 receptor antagonist
clinical
Initial Roche studies could be completed May or June 2020; Phase II open-label study in Italy active (April 2020), Phase III Roche global trial enrolling May 2020, Roche trial (+ remdesivir) to start June 2020; primary endpoints Sept 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04317092, NCT04320615, NCT04310228, ChiCTR2000030894, NCT04306705, ChiCTR2000030442, ChiCTR2000029765, NCT04322773, NCT04345445, NCT04331795, NCT04332094, NCT04346355, NCT04359667, NCT04332913, NCT04335071, NCT04356937, NCT04361032, NCT04315480, NCT04339712, NCT04333914, NCT04361552, NCT04330638, NCT04331808, NCT02735707, NCT04349410, NCT04363736, NCT04372186, NCT04363853, EudraCT 2020-001754-21, EudraCT 2020-001500-41, EudraCT 2020-001246-18, EudraCT 2020-001039-29, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT 2020-001854-23, NCT04381936 (RECOVERY), NCT04409262, EudraCT 2020-001903-17
Regeneron/ NIAID
Antibody combination REGN-COV2 (REGN10933+REGN10987) against the spike protein
clinical
Joined Operation Warp Speed in July 2020; Phase III prevention trial with NIAID starts July 2020; Phase II stage of I/II/III treatment trial started July 2020; Phase III starts Aug 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04425629, NCT04426695, NCT04452318
Roivant Sciences
Gimsilumab, anti-granulocyte-macrophage colony stimulating factor monoclonal
clinical
Phase II study started in April 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04351243
Staidson/ Pivotal
BDB-100, monocloncal anti-C5a antibody
clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Swedish Orphan Biovitrum
Gamifant (emapalumab), anti-interferon gamma antibody
clinical
Phase II/III recruiting April 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04324021
Tang-Du Hospital
meplazumab, anti-CD147 antibody
clinical
Results released July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Chinese National Science and Technology Major Project
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04275245
Tychan/ SingHealth Investigational Medicine Unit
TY027, monoclonal antibody targeting SARS-CoV-2
clinical
Phase I started June 2020; efficacy data expected 3Q 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04429529
University of Hong Kong (BMS)
Opdivo (nivolumab), PD-1 blocking antibody
clinical
Phase II study not yet recruiting
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04356508, NCT04333914, NCT04405271, NCT04343144
Various global research sponsors
Prolastin, alpha-1 anti-trypsin antibody
clinical
Phase II trial recruiting July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
EudraCT 2020-001391-15, NCT04385836, NCT04495101
Vir Biotechnology / GSK / Samsung / WuXi Biologics / Biogen
VIR-7831 and VIR-7832, antibodies from recovered SARS patients
clinical
Start Phase II ~July-September 2020; Dosing began Aug 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Abcore
Single domain antibodies (sdAbs), engineered monoclonal antibody derived from camelids
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Ablexis / AlivaMab Discovery Services / Berkeley Lights Collaborate
Antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Adagio Therapeutics
Antibodies binding to a piece of the spike protein found on multiple coronaviruses including SARS-CoV-2
pre-clinical
Phase I trial expected to start by the end of 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Alliance - Proteona/ NMI/ NUS Enterprise/10X Genomics; NovogeneAIT/ Twist Bioscience/ University Hospitals
Antibody for immunocompromised patients
pre-clinical
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Amgen/ Adaptive Biotechnologies
Antibodies from recovered COVID-19 patients
pre-clinical
Phase I trial expected to start ~October 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
AstraZeneca / US Army Medical Research Institute of Infectious Diseases (USAMRIID) / University of Maryland School of Medicine
Antibodies targeting the S protein from convalescent serum, humanized mice, and phage display
pre-clinical
Phase I/II trials begin in summer 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Atreca / BeiGene / IGM Biosciences/ Singlomics
Novel IgM and IgA antibodies
pre-clinical
Phase I/II trials to begin in Oct 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04511949
CSL Behring / SAb Biotherapeutics
SAB-185, Polyclonal hyperimmune globulin (H-IG)
pre-clinical
Phase I starts early summer 2020; Dosing to start August 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04468958, NCT04469179
CSL Behring Australia
COVID-19 Immunoglobulin, plasma derived
pre-clinical
Phase I/II trials began June 2020; recruitment began Aug 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Celltrion
Super-antibody or antibody cocktail to target potential mutations of SARS-CoV-2
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Centivax (Distributed Bio)
Antibody
pre-clinical
Released hamster study results in June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Chelsea and Westminster Hospital, Imperial College London
Antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
UK Government
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
CoVIg-19 Plasma Alliance (Takeda, CSL Behring, Biotest AG, Bio Products Laboratory, LFB, and Octapharma, ADMA Biologics, BioPharma Plasma, GC Pharma, Sanquin)/Gates Foundation/ NIAID/ Microsoft
Polyclonal hyperimmune globulin (H-IG), unbranded
pre-clinical
Phase I trials start in summer 2020; To patients between December 2020 and December 2021
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Cologne University Hospital/ German Center for Infection Research/ Boehringer Ingelheim
Antibodies from recovered COVID-19 patients
pre-clinical
Clinical trials to start in 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Columbia University Irving Medical Center
Mix of neutralizing antibodies isolated from recovered COVID-19 patients
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Costa Rican Social Security Fund (CCSS)/ The University of Costa Rica (UCR)/ Clodomiro Picado Institute
Antibodies from recovered COVID-19 patients
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Edesa Biotech / Light Chain Bioscience (NovImmune)
Monocloncal antibodies, CXC10 antagonist
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Eli Lilly/ Sanford Burnham Prebys Medical Discovery Institute
Neutralizing antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Emergent BioSolutions
Horse plasma product (COVID-EIG)
pre-clinical
Phase II trials begin ~August 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Same equine hyperimmune platform as FDA-approved botulism anti-toxin (BAT) is produced
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Emergent BioSolutions/ National Institute of Allergy and Infectious Diseases (NIAID)/ Mt Sinai Health System/ ImmunoTek Bio Centers
Polyclonal hyperimmune globulin (H-IG)
pre-clinical
Phase II trials begin ~August 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Same human hyperimmune platform as FDA-approved anthrax treatment (Anthrasil) and smallpox vaccine complications (VIGIV) were developed
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Fab'entech
Polyclonal antibodies
pre-clinical
Expected to begin Phase I/II trials in early 2021
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
FairJourney Biologics / Iontas
Antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
GC Pharma/ Korea National Institute of Health
GC5131A, plasma derived therapy
pre-clinical
Phase II/III to start in July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Generation Bio / Vir Biotechnology
Non-viral gene therapy to produce monoclonal antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
GigaGen
rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin), polyclonal antibodies
pre-clinical
Phase I trial expected to start early 2021
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Grifols
Polyclonal hyperimmune globulin (H-IG)
pre-clinical
Phase I trial expected to start July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04432324, NCT04480424
Grifols
Antibodies from recovered COVID-19 patients
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Harbour BioMed / Erasmus MC / Utrecht University / Mount Sinai Health System / AbbVie
Antibody 47D11
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
IGY Life Sciences/ MMS Holdings/ Canadian Government National Microbiology Lab
IgY-110, anti-CoV-2 antibody (nasal spary application)
pre-clinical
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
ImmunoPrecise Antibodies
Monoclonal antibody cocktail
pre-clinical
Lead candidates identified June 2020, pre-clinical studies to start summer 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
North Dakota Bioscience Innovation Grant
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Immunome
Novel biosynthetic convalescent plasma (BCP)
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Department of Defense (DoD)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Innovent Biologics
Antibodies from recovered COVID-19 patients
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Ligand Pharmaceuticals
Antibodies (OmniChicken platform)
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Ligand Pharmaceuticals
Antibodies (OmniRat platform)
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Medicago / Laval University's Infectious Disease Research Centre
Antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Canadian Institutes for Health Research (CIHR)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Prellis Biologics
Antibodies
pre-clinical
Phase I trial could begin as early as Sept 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Public Health England (Stuart Dowall)
Purified ovine immunoglobulin from immunized sheep
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
UK Government
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Rosalind Franklin Institute/ Oxford University/ Diamond Light Source/ Public Health England
Nanobodies from Llamas
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Sorrento Therapeutics/ Mount Sinai Health System/ Columbia University
COVI-SHIELD/COVI-TRACE/COVI-GUARD antibody cocktail that binds to three different epitopes
pre-clinical
Start Phase II trial Q3 2020; FDA cleared for Phase I for COVI-GUARD (STI-1499) in hospitalized COVID-19 patients
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04454398
Tiziana Life Sciences
TZLS-501, an anti-interleukin-6 receptor monoclonal antibody (inhalation technology in development-Foralumab anti-CD3 monoclonal antibody)
pre-clinical
Plan to initiate Phase I in Q1 2021
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Tsinghua University/ Third People's Hospital of Shenzhen/ Brii Biosciences
BRII-196 and BRII-198, Antibodies from recovered COVID-19 patients
pre-clinical
Phase I trials recruiting July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04479644, NCT04479631
University of Texas at Austin/ US National Institutes of Health/ Ghent University
Linked nanobody antibody
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Vanderbilt Vaccine Center / AstraZeneca / IDBiologics
Combo of two antibodies (AZD7442)
pre-clinical
Phase I trial began August 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Defense Advanced Research Projects Agency/ Dolly Parton/ Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04507256
Virna Therapeutics/ University of Toronto
Neutralizing antibodies
pre-clinical
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Xbiotech/ BioBridge Global
Antibodies from recovered COVID-19 patients
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Developer / Researcher
Product Description
PHASE
Next Steps
Acer Therapeutics / US National Center for Advancing Translational Sciences (NCATS)
emetine hydrochloride
clinical
Phase II/III to start in Q3 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
To treat viral hepatitis and varicella-virus
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Ansun Biopharma/ Renmin Hospital of Wuhan University
DAS181, recombinant sialidase (nebulized)
clinical
Individual patient expanded access finding released in May 2020; Phase II/III started enrolling in May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of lower respiratory tract parainfluenza virus infections and severe influenza infections
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT03808922, NCT04354389, NCT04298060, NCT04324489, NCT04460547
Ascletis / Chinese research sponsors
Ganovo (danoprevir), hepatitis C virus NS3 protease inhibitor; ritonavir; interferon, approved in China to treat Hepatitis C
clinical
Small open label trial completed and results released in March 2020; Larger open label trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of Hepatitis C
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04291729 NCT04345276
Ascletis/ Chinese research sponsors
ASC09, HIV protease inhibitor
clinical
Phase III trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of HIV/AIDS
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04261907 NCT04261270
Atea Pharmaceuticals
AT-527, oral purine nucleotide prodrug
clinical
Phase II trial to start May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of Hepatitis C infections
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04396106
Bausch Health
Virazole (ribavirin for inhalation solution)
clinical
Phase II recruiting May 2020; Individual patient expanded access
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04356677, NCT04460443, NCT04392427, NCT04276688
Beech Tree Labs
BTL-tml
clinical
FDA cleared trial July 2020, trial to start July/Aug 2020 with results available Fall 2020; Has been used in 36 patients anecdotally; Phase II trial started August 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of herpes virus infections
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04522830
BioCryst Pharmaceuticals
galidesivir
clinical
Phase Ib recruiting May 2020
n/a
Funder
Funder
n/a
National Institute of Allergy and Infectious Diseases (NIAID)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of yellow fever
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT03891420
Bukwang Pharm
Levovir (clevudine)
clinical
Phase II trial not yet recruiting
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04347915
Fujifilm Toyama Chemical/ Zhejiang Hisun Pharmaceuticals/ numerous trials with global research sponsors/ Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School/ Glenmark Pharmaceuticals
Favilavir/ Favipiravir/ T-705/ Avigan, licensed in Japan to treat influenza
clinical
Fuijfilm trial initial results released July 2020; Glenmark Phase III trial in India top-line results released July 2020 (Glenmark)
n/a
Funder
Funder
n/a
Life Arc (FLARE trial; PIONEER trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04303299, NCT04310228, ChiCTR2000029548, ChiCTR2000029496, ChiCTR2000029544, ChiCTR2000030254, NCT04336904, NCT04333589, NCT04345419, EudraCT 2020-001435-27, NCT04356495, NCT04425460, NCT04373733, EudraCT 2020-001449-38, EudraCT 2020-001528-32, EudraCT 2020-001904-41, NCT04468087, NCT04376814, NCT04411433, NCT04445467, NCT04402203, NCT04392973, NCT04349241, NCT04346628, NCT04448119, NCT04475991, NCT04358549, NCT04434248, NCT04359615, NCT04464408, NCT04387760, NCT04474457, NCT04351295, EudraCT Number: 2020-002106-68,  NCT04529499
Gilead; World Health Organization SOLIDARITY trial; National Institute of Allergy and Infectious Diseases (NIAID)'s Adaptive COVID-19 Treatment Trial; Feinstein Institutes; I-SPY COVID
remdesivir, nucleotide analog
clinical
Additional Phase 3 trial data released July 2020; Phase 1a trial of inhalant version started July 2020; EU grants conditional authorization July 2020; Phase 2/3 trial started in pediatric patients in June 2020; FDA issued an Emergency Use Authorization May 2020; Expanded EUA access Aug 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of Ebola
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04257656, NCT04252664, NCT04292730, NCT04292899, NCT04280705, EudraCT 2020-000936-23, NCT04315948, NCT04302766, NCT04323761, NCT04349410, NCT04401579, EudraCT 2020-001052-18, ISRCTN83971151 (Solidarity), EudraCT 2020-001366-11 (Solidarity Spain), EudraCT 2020-000982-18 (Norway Solidarity), EudraCT 2020-001784-88 (Finland Solidarity), EudraCT 2020-001549-38 (Solidarity Germany), NCT04330690, NCT04431453, NCT04409262, NCT04321616, EudraCT 2020-001448-24, NCT04365764, NCT04410354, NCT04365725, NCT04480333 (inhaled remdesevir + neurosivir), NCT04488081, EudraCT 2020-000841-15, EudraCT 2020-001453-49, EudraCT 2020-000842-32, EudraCT 2020-001803-17, EudraCT 2020-002060-31, NCT04501978
Global hospital testing (AbbVie); World Health Organization SOLIDARITY trial (studying lopinavir/ ritonavir with and without interferon beta); University of Oxford RECOVERY trial; REMAP-CAP global trial; Univ. of College, London
Kaletra/Aluvia (lopinavir/ritonavir), HIV-1 protease inhibitor
clinical
WHO discontinues lopinavir-ritonavir arm in the SOLIDARITY trial July 2020; RECOVERY trial results released June 2020 and stopped that trial arm
n/a
Funder
Funder
n/a
UK Government (University of Oxford RECOVERY trial); Life Arc (FLARE trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04303299, NCT04255017, ChiCTR2000029548, ChiCTR2000029539, EudraCT 2020-000936-23, NCT04307693, NCT04315948, NCT04252885, NCT04276688, NCT02735707, NCT04321993, 2020-001113-21, NCT04286503, NCT04328012, NCT04346147, NCT04350671, NCT04466241, EudraCT 2020-001825-29, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT number: 2020-001321-31, ISRCTN83971151 (Solidarity), EudraCT 2020-001366-11 (Solidarity Spain), EudraCT 2020-001528-32, EudraCT 2020-001723-13, EudraCT 2020-000982-18 (Norway Solidarity), EudraCT 2020-001549-38 (Solidarity Germany), NCT04381936 (RECOVERY), NCT04386070, NCT04372628, NCT04330690, EudraCT 2020-001448-24, NCT04435587, NCT04425382, NCT04376814, EudraCT 2020-001605-23, NCT04251871, NCT04275388, NCT04521400, NCT04499677
Hospital Universitario Infanta Leonor/ Viiv Healthcare; Hospital General de México Dr. Eduardo Liceaga; Rhode Island Hospital
Selzentry (maraviroc), a CCR5 co-receptor antagonist
clinical
Phase II trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04475991, NCT04441385, NCT04435522
Hospital do Coracao
Sofusbuvir
clinical
Phase II/III trial not yet recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04468087
Multiple global research sponsors
Prezcobix (darunavir, HIV-1 protease inhibitor/cobicistat, CYP3A inhibitor)
clinical
Phase III trials recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000029541, NCT04252274, NCT04303299, NCT04304053, EudraCT 2020-001528-32, NCT04435587, NCT04425382
Multiple global research sponsors
Arbidol (umifenovir), licensed in Russia and China for treatment of respiratory viral infections
clinical
Phase IV trials recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04252885, NCT04350684, NCT04286503, NCT04260594, NCT04273763
NeuroActiva
Neurosivir (NA-831)
clinical
Phase II/III trial recruiting July 2020 (neurosivir); Phase I trial recruiting July 2020 (inhaled remdesevir + neurosivir)
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Alzheimer's disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04452565, NCT04480333 (inhaled remdesevir + neurosivir), NCT04540185
Plan Nacional sobre el Sida
Truvada (emtricitabine and tenofovir, both HIV-1 nucleoside analog reverse transcriptase inhibitors)
clinical
Phase III trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000029468, NCT04334928, NCT04405271
Ridgeback Biotherapeutics / Drug Innovation Ventures at Emory (DRIVE)/ Merck
EIDD-2801, oral ribonucleoside analog
clinical
Phase II trial started June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04405739, NCT04405570, NCT04392219
Roche; REMAP-CAP global trial
Tamiflu (oseltamivir), neuraminidase inhibitor
clinical
REMAP-CAP trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04303299, NCT04255017, NCT04261270, NCT02735707, NCT04338698, NCT04371601, EudraCT 2015-002340-14 (REMAP-CAP), NCT04457609
Various global research sponsors
Atazanavir, protease inhibitor
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04459286, NCT04468087, NCT04452565
Various global research sponsors
Daklinza (daclatasvir), hepatitis C virus (HCV) NS5A inhibitor
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04443725, NCT04468087
Agastiya Biotech
AB001
pre-clinical
Phase I to start in 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Anivive Lifesciences
GC376, protease inhibitor
pre-clinical
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Cidara Therapeutics
antiviral Fc conjugates
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Cocrystal Pharma
Antiviral compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ISR Immune System Regulation
ISR-50
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
SCORE consortium (universities of Aix-Marseille, Leuven, Utrecht, Bern, and Lubeck), the Helmholtz Centre for Infection Research, and Janssen Pharmaceutica NV
Antiviral drug combinations
pre-clinical
Unknown
n/a
Funder
Funder
n/a
EU Commission (Horizon 2020 Program)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Selva Therapeutics 
SLV213, cysteine protease inhibitor
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Stanford University/ US Department of Energy's Lawrence Berkeley National Laboratory
Prophylactic antiviral CRISPR in human cells (PAC-MAN)
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ViralClear Pharmaceuticals
Vicromax, broad spectrum antiviral
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
AgenTus Therapeutics (Agenus) 
AgenT-797, allogeneic invariant natural killer T cells
clinical
FDA cleared Phase I trial June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Aspire Health Science
ACT-20, allogeneic cell preparation of mesenchymal stem cells from umbilical cord tissue
clinical
Phase I/II trial FDA cleared June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04398303
Athersys / The University of Texas Health Science Center at Houston
MultiStem, bone marrow stem cells
clinical
Phase II/III trial recruiting May 2020
n/a
Funder
Funder
n/a
Medical Technology Enterprise Consortium (MTEC)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute Respiratory Distress Syndrome; Stroke
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04367077
Caladrius Biosciences
CLBS119, autologous peripheral blood-derived CD34+ cell therapy
clinical
Phase II trial expected to start Q3 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Capricor Inc.
CAP-1002, allogenic cardiosphere-derived cells
clinical
Expanded access protocol trial ongoing May 2020; FDA approved IND in August 2020 for Phase II trial
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Duchenne muscular dystrophy
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04338347
Cellenkos
CK0802, allogeneic cell therapy containing T-regulatory cells from umbilical cord blood processed to express lung homing markers on the cell surface
clinical
Two case reports released July 2020; FDA cleared Phase I trial July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04468971
Celltex
Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs) and allogeneic MSCs
clinical
FDA approves Phase II trial June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Injuries, Pain, and Autoimmune, Vascular and Other Disease, including Inflammatory lung conditions, pneumonia, and chronic obstructive pulmonary disease (COPD)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04428801
Celularity/ Lung Biotechnology PBC/ California Institute for Regnerative Medicine (CIRM)
CYNK-001, allogeneic, natural killer cell therapy
clinical
Phase I/II study recruiting August 2020; Dosing began for Phase 1/2
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various hematologic cancers and solid tumors
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04365101
Cynata Therapeutics
Mesenchymal stem cells
clinical
Phase II to start in July 2020 in Australia
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Daewoong
DWP710, a mesenchymal stem cell therapy
clinical
Phase I trial started July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Enlivex Therapeutics
Allocetra, early apopototic cells
clinical
Phase II trial started May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Sepsis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Hope Biosciences/Daewoong Pharmaceutical Co. LTD/ Other global research sponsors
Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)
clinical
Phase II started in April 2020, Phase I efficacy trial began Aug 2020
n/a
Funder
Funder
n/a
Hope Biosciences Stem Cell Research Foundation
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Rheumatoid arthritis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04348435, NCT04349631, NCT04362189, NCT04535856
Lattice Biologics
AmnioBoost, concentrated allogeneic MSCs and cytokines derived from amniotic fluid
clinical
Phase I enrolling April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Mesoblast/ Cardiothoracic Surgical Trials Network
Ryoncil (remestemcel-L), allogenic mesenchymal stem cells
clinical
Expanded access protocol started for children July 2020; Phase II/III trial started May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Graft versus host disease and other rare diseases, chronic obstructive pulmonary disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04366830, NCT04371393
Naturecell Co. LTD
Astrostem-V, Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)
clinical
Phase I/IIa trial approved by South Korea Ministry of Food and Drug Safety in March 2020; Phase I/II efficacy trial to start Dec 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04486001, NCT04527224
Numerous trials with global research sponsors
Mesenchymal stem cells
clinical
Phase I trials ongoing May 2020; Phase I/II trials recruiting May 2020; Phase II/III trial recruiting May 2020; Phase 2 trial enrollment Sept 2020-EXIT COVID-19
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
30 trials listed in clinicaltrials.gov, including: ChiCTR2000029990, NCT04315987, NCT04302519, NCT04288102, NCT04313322, NCT04273646, NCT04371601, NCT04315987, NCT04252118, NCT04336254, NCT04339660, NCT04371601, NCT04366063, NCT04467047, NCT04461925, NCT04444271, NCT04493242
Pluristem Therapeutics/ BIH Center for Regenerative Therapy/ Berlin Center for Advanced Therapies
PLX cell product, placenta-based cell therapy
clinical
Phase II trial recruiting July 2020; Results from individual patient expanded access released in April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various conditions
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04389450
Red de Terapia Celular (TerCel)
MSV_allo, allogenic mesenchymal stem cells
clinical
Phase I/II trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04361942
Therapeutic Solutions International
StemVacs, universal donor natural killer cell-based therapy
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Cancer
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Trustem Cell Therapy
Umbilical cord-derived mesenchymal stem cells
clinical
Phase II trial to start in Columbia in July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04429763
Vitro Biopharma/ Global Institute of Stem Cell Therapy and Research
AlloRx stem cells, umbilical cord mesenchyma stem cell therapy
clinical
Individual expanded access results released July 2020; IND submitted to FDA April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Inflammatory conditions
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AgeX Therapeutics/ ImStem Biotechnology
IMS001, human embryonic stem cell-derived mesenchymal stem cells (hES-MSC)
pre-clinical
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AlloVir / Baylor College of Medicine
Allogeneic T-cell therapies
pre-clinical
Phase I not yet recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04401410
Baylx, Inc. 
BX-U001, allogeneic umbilical cord derived mesenchymal stem cell (hUC-MSC)
pre-clinical
FDA cleared Investigational New Drug (IND) application for BX-U001
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Rheumatoid arthritis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BioCardia
BCDA-4, bone marrow-derived allogenic neurokinin-1 receptor positive mesenchymal stem cells
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CAR-T (Shanghai) Biotechnology
Dental pulp-derived mesenchymal stem cells
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Citius/Novellus
NoveCite cells (NC-MSCs), mesenchymal stem cells derived from a single donor's fibroblasts
pre-clinical
Phase I trial to start by end of 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Duke-NUS Medical School
Chimeric antigen receptors (CAR)/T cell receptors (TCR)-T cell therapy
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
GC LabCell / KLEO Pharmaceuticals
Natural killer cell-based therapy
pre-clinical
Begin Phase I by end of 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ImmunityBio / NantKwest
haNK, natural killer cells
pre-clinical
Pre-IND submitted to FDA in May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ImmunityBio / NantKwest / Be The Match BioTherapies
Bone marrow-derived allogenic mesenchymal stem cells (BM-Allo-MSC)
pre-clinical
Phase Ib trial to start June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Kangstem Biotech
Furestem RA, allogenic umbilical cord blood-derived stem cell therapy
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Regeneris Medical
Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs)
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
SMSbiotech
Small mobile stem (SMS) cells
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sentien Biotechnologies
SBI-101, biologic/device combo product with allogeneic mesenchymal stem cells and a phasmapheresis device
pre-clinical
Phase I/II trial to start August 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04445220
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
ALung Technologies
Hemolung Respiratory Assist System
clinical
pneum
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute Exacerbation of Chronic Obstructive Pulmonary Disease; Acute Respiratory Distress Syndrome (ARDS)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Abiomed
Impella RP heart pump
clinical
FDA issued an Emergency Use Authorization for Impella heart pumps in COVID-19 therapy on May 29, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Baxter
Oxiris Blood Purification Filter
clinical
FDA issued an Emergency Use Authorization on April 23, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04478539
Bellerophon; Ohio State University Wexner Medical Center
INOpulse
clinical
Phase III trial began July 2020; Expanded access trial ended July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04398290, NCT04358588 (Expanded access), NCT04421508
Beyond Air Ltd
LungFit (with ultra-high concentrations of nitric oxide)
clinical
Phase II trial enrolling July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Bronchiolitis and nontuberculous mycobacteria
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04397692, NCT04456088
CytoSorbents Corporation
CytoSorb (blood purification device, extracorporeal cytokine adsorber))
clinical
Individual patient expanded access; FDA issued an Emergency Use Authorization on April 10, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04324528, ChiCTR2000030475, NCT04344080, DRKS00021447, NCT04385771, NCT04344080, NCT04324528
ExThera Medical
Seraph100MicrobindAffinity Blood Filter (Seraphy 100), approved in the EU for pathogen reduction
clinical
DOD to fund a multi-center trial June 2020; FDA issued an Emergency Use Authorization on April 17, 2020
n/a
Funder
Funder
n/a
US Department of Defense (DOD)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Fresenius Medical
MultiFiltrate PRO System and multiBic/multiPlus Solutions, continuous renal replacement therapy (CRRT)
clinical
FDA issued an Emergency Use Authorization on April 30, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Terumo BCT Inc / Marker Therapeutics AG
Extracorporeal blood purification (EBP) devices
clinical
FDA issued an Emergency Use Authorization on April 9, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
electroCore
gammaCore Sapphire CV, vagus nerve stimulation device
clinical
FDA granted Emergency Use Authorization July 10, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Asthma
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
Mateon Therapeutics
OT-101, a TGF-Beta antisense drug candidate
clinical
Phase II study IND submitted to FDA on April 27, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AIM ImmunoTech/ National Institute of Infectious Diseases in Japan/ Roswell Park Comprehensive Cancer Center
Ampligen; (rintatolimod)
pre-clinical
Phase I/II trial of Ampligen (rintatolimod), in combination with interferon alfa-2b, in cancer patients with COVID-19 not yet recruiting July 2020
n/a
Funder
Funder
n/a
National Cancer Institute
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04379518
Neurimmune / Ethris
Inhaled mRNA
pre-clinical
Phase I to start Q4 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sarepta Therapeutics / US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Antisense oligonucleotides, peptide conjugated
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sirnaomics
RNAi - testing 150 RNAis
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vir Biotech / Alnylam Pharmaceuticals
VIR-2703 (ALN-COV) siRNA candidate
pre-clinical
Phase I to start by the end of 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
Anixa Biosciences / OntoChem
Screening for antiviral drug candidates
pre-clinical
Initial in silico screening completed July 2020, testing identified compounds in pre-clincial studies July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
COVID-19 Therapeutics Accelerator
Scanning compound libraries
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Gates Foundation / Wellcome / Mastercard Impact Fund
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Enanta Pharmaceuticals
Screening new drugs + library of antiviral compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Exscalate4Cov, public-private consortium
Screening a chemical library of 500 billion molecules
pre-clinical
Unknown
n/a
Funder
Funder
n/a
European Commision's Horizon 2020
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Healx
Artificial intellegence-based screening to identify repurposed drug combinations
pre-clinical
Combinations will be ready for pre-clinical testing in May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Janssen Pharmaceutical Companies
Scanning library of antiviral compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Materia Medica/Cyclica/Manin
Repurposing antiviral drug candidates
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Merck
Scanning compounds to repurpose
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Novartis
Scanning compounds to repurpose
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Nuritas
AI-based screening to identify a peptide cocktail
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Partnership for Advanced Computing in Europe (PACE)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Pfizer
Scanning antiviral compounds previously in development
pre-clinical
Lead candidate (protease inhibitor) to start Phase I trial in Q3 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Quantitative Biosciences Institute Coronavirus Research Group
Reviewing existing drugs and compounds through mapping viral-human protein interactions
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Queens University Belfast
Scanning compounds to repurpose
pre-clinical
Unknown
n/a
Funder
Funder
n/a
UK Government
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sanford Burnham Prebys Medical Discovery Institute, the University of Hong Kong, Scripps Research, UC San Diego School of Medicine, the Icahn School of Medicine at Mount Sinai and UCLA
Identifying drugs to repurpose
pre-clinical
Testing drugs ONO5344 and VBY825 July 2020; identified 30 known drugs that inhibit SARS-CoV-2 replication
n/a
Funder
Funder
n/a
US Department of Defense; California Institute for Regenerative Medicine
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Shionogi / Hokkaido University Research Center for Zoonosis Control
Identify novel drugs
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Southwest Research Institute
Screening drug compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Henry M. Jackson Foundation for the Advancement of Military Medicine
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Takeda
Scanning compounds to repurpose
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
The Castleman Disease Collaborative Network and the Center for Study & Treatment of Inflammatory Lymphadenopathies
Identifying drugs to repurpose
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vanda Pharmaceuticals / University of Illinois at Chicago
Screening of drug compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vir Biotechnology / GSK
Identify anti-coronavirus compounds that target cellular host genes
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Wyss Institute
Identify FDA-approved drugs to repurpose to prevent or treat COVID-19
pre-clinical
Unknown
n/a
Funder
Funder
n/a
US Defense Advanced Research Projects Agency (DARPA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
I-SPY COVID Trial (Aerpio Pharmaceuticals)
Razoprotafib, Tie 2 activating compound (AKB-9778)
clinical
Second trial to start in August 2020; Dosing began Phase 2 platform/I-SPY trial Sept 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
I-SPY COVID Trial (Allergan)
Cenicriviroc, chemokine receptor 2 and 5 dual antagonist
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Non-Alcoholic SteatoHepatitis (NASH)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
I-SPY COVID Trial (Takeda)
Firazyr (icatibant), bradykinin B2 antagonist
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
4D Pharma
MRx-4DP0004, strain of Bifidobacterium breve isolated from the gut microbiome of a healthy human
clinical
Phase II enrolling July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Asthma
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04363372, EudraCT 2020-001597-30
ACCORD trial; University Hospital, Ghent/UCB Pharma 
Zilucoplan, a synthetic macrocyclic peptide inhibitor of the terminal complement protein C5
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Myasthenia gravis; immune-mediated necrotizing myopathy, ALS
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001736-95 (ACCORD Trial), NCT04382755
AI Therapeutics/ Yale University
LAM-002A (apilimod dimesylate), PIKfyve kinase inhibitor
clinical
Phase II trial started July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Lymphangioleiomyomatosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04446377
ARMS Pharmaceutical / UH Cleveland Medical Center / Case Western Reserve University
ARMS-1
clinical
Trial starts April 2020
n/a
Funder
Funder
n/a
Cleveland Foundation
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Influenza prophylaxis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Aarhus University
senicapoc
clinical
Phase II trial ongoing July 2020
n/a
Funder
Funder
n/a
The Danish Government
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Sickle cell anemia; Alzheimer's disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001420-34
Abivax
ABX464
clinical
Phase IIb/III trial started July 2020, top line results expected in 2020
n/a
Funder
Funder
n/a
Bpifrance
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Ulcerative colitis; rheumatoid arthritis; hepatocellular carcinoma
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04393038
Aldeyra Therapeutics
ADX-629, orally available reactive aldehyde species (RASP) inhibitor
clinical
IND submission to FDA in June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Systemic immune-mediated diseases
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Aldeyra Therapeutics
ADX-1612, HSP 90 inhibitor
clinical
IND submission to FDA in June 2020; FDA approval to begin Phase II trials in Sept 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Algernon Pharmaceuticals
Cerocal (ifenprodil), NP-120, an NDMA receptor glutamate receptor antagonist targeting Glu2NB
clinical
Phase IIb/III trial to start July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Idiopathic Pulmonary Fibrosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04382924
Amarin Corp
Vascepa (icosapent ethyl), a form of eicosapentaenoic acid
clinical
Unknown
n/a
Funder
Funder
n/a
Estudios Clínicos Latino América
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04412018, NCT04460651
Amgen; I-SPY COVID trial/Takeda/AbbieVie
Otezla (apremilast), inhibitor of phosphodiesterase 4 (PDE4)
clinical
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (I-SPY_COVID) starts July 2020; Enrolling patients August 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04488081
Apeptico/ Medical University Vienna
solnatide (synthetic molecule with a structure based on the lectin-like domain of human Tumour Necrosis Factor alpha)
clinical
Phase II trials ongoing July 2020; Individual expanded access in Austria April 2020
n/a
Funder
Funder
n/a
EU Commission (Horizon 2020 Program)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pneumonia, sepsis, ARDS, Primary Graft Dysfunction, and pulmonary dysfunctions
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001244-26
Applied Biology/ Brown University/ Corpometria Institute
dutasteride, anti-androgen
clinical
Unknown
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04446429
Applied Therapeutics/ numerous New York City hospitals
AT-001, aldose reductase inhibitor
clinical
Phase II recruiting July 2020; Individual patient expanded access
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Diabetic cardiomyopathy
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04365699
Arch Biopartners
Metablok (LSALT peptide), selective dipeptidase-1 antagonist
clinical
FDA and Health Canada approved Phase II trial start in July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Lung and Kidney Inflammation
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04402957
AstraZeneca/ Saint Luke's Mid America Heart Institute; Cambridge University Hospitals NHS Foundation Trust; TACTIC-E trial studying dapagliflozin + ambrisentan
Farxiga (dapagliflozin), sodium-glucose cotransporter 2 (SGLTs) inhibitor
clinical
Phase III study started in April 2020 (AstraZeneca)
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Heart failure; Chronic kidney disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04350593, NCT04393246
AstraZeneca; ACCORD study/Rigel Pharmaceuticals
Calquence (acalabrutinib), Bruton's tyrosine kinase (BTK) inhibitor
clinical
Case series results released June 2020; ACCORD Phase II trial to start May 2020; Phase 2 trial (fostamatinib) starts Sept 2020
n/a
Funder
Funder
n/a
UK Government (ACCORD study)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04346199, NCT04380688, EudraCT 2020-001736-95 (ACCORD Trial), EudraCT 2020-001644-25, NCT04497948
BerGenBio; ACCORD study
bemcentinib, selective AXL kinase inhibitor
clinical
ACCORD trial started June 2020, top line data expected summer 2020
n/a
Funder
Funder
n/a
UK Government (ACCORD study)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001736-95 (ACCORD Trial)
Beth Israel Deaconess, the University of Colorado Anschultz Medical Campus, and Denver Health (Genentech); University College London; Boehringer Ingelheim
Activase (alteplase), tissue plasminogen activator (tPA)
clinical
Phase II trial recruiting; Individual patient expanded access
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04357730, NCT04356833, EudraCT 2020-001640-26, NCT04453371
BioAegis Therapeutics Inc.
recombinant human plasma gelsolin (rhu-pGSN)
clinical
Phase II trial to start recruiting in Spain in July 2020, Enrollment August 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Community-acquired pneumonia
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04358406
Biohaven/ Thomas Jefferson University
vazegepant, CGRP receptor antagonist
clinical
Phase II/III recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute migraine
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04346615
Biomarck Pharmaceuticals
BIO-11006, inhaled peptide
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute Respiratory Distress Syndrome; Non-Small Cell Lung Cancer; Chronic Obstructive Pulmonary Disease (COPD)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Blade Therapeutics
BLD-2660, synthetic small molecule inhibitor of calpain (CAPN) 1, 2, and 9
clinical
Enrollment completed for Phase II trials
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04334460
CTI Biopharma
pacritinib, oral kinase inhibitor with specificity for JAK2, IRAK1 and CSFIR
clinical
Phase III trial recruiting July 2020, results expected by the end of 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Myelofibrosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04404361
CalciMedica
Auxora (CM4620-IE), calcium release-activated calcium (CRAC) channel inhibitor
clinical
Open label phase II trial top line data released July 2020; Phase II trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pancreatitis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04345614
Can-Fite BioPharma
piclidenoson, A3 adenosine receptor agonist
clinical
IND (investigational new drug application) expected to be filed with FDA by end of July 2020; IND approved Sept 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Rheumatoid arthritis; psoriasis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04333472
Center for Clinical Metabolic Research, Gentofte Hospital
Entresto (sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker)
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001544-26
Chimerix
DSTAT (dociparstat sodium), glycosaminoglycan derivative of heparin
clinical
Phase II/III trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute myeloid leukemia
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04389840
Cyclacel Pharmaceuticals / University of Edinburgh
fadraciclib (CYC065), cyclin-dependent kinase (CDK)2/9 inhibitor
clinical
Unknown
n/a
Funder
Funder
n/a
LifeArc
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Cyclacel Pharmaceuticals / University of Edinburgh
roscovitine seliciclib, cyclin-dependent kinase (CDK)2/9 inhibitor
clinical
Unknown
n/a
Funder
Funder
n/a
LifeArc
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Rheumatoid arthritis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Dompe farmaceutici (as part of Exscalate4CoV)
raloxifene (Evista), an estrogen agonist/antagonist
clinical
Unknown
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Eagle Pharmaceuticals / Amneal Pharmaceuticals / Alcami Corporation / Hackensack University Medical Center
Ryanodex (dantrolene sodium), skeletal muscle relaxant
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Eiger BioPharmaceuticals, Inc./ Johns Hopkins University
Peginterferon lambda
clinical
Phase II began in April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Hepatitis Delta
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04331899, NCT04344600
Eisai
Eritoran, TLR-4 antagonist
clinical
Added to REMAP-COVID trial in June 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Sepsis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Evelo Biosciences/ Rutgers University/ Robert Wood Johnson University Hospital/ TACTIC-E trial (Cambridge University Hospitals NHS Foundation Trust)
EDP1815, oral single strain of microbe
clinical
Part of Phase II/III Phase TACTIC-E trial and interim data expected 4Q 2020; Phase II US trial to start August 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Psoriasis and Atopic Dermatitis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04393246
Exvastat Ltd / Global sponsors
Gleevac (imatinib), kinase inhibitor
clinical
Phase II and Phase III trials recruiting July 2020
n/a
Funder
Funder
n/a
Innovative Medicines Initiative
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04346147, NCT04357613, NCT04356495, NCT04422678, NCT04394416, EudraCT 2020-001435-27, EudraCT 2020-001321-31
FSD Pharma
FSD-201 (ultramicronized palmitoylethanolamide)
clinical
Phase I topline results released June 2020; IND submitted to FDA Aug 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Respiratory infections
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Faron Pharmaceuticals / REMAP-CAP global trial/ WHO SOLIDARITY trial/ various global researchers
Traumakine (interferon beta 1-a)
clinical
Results from various trials released June 2020; REMAP-CAP trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT02735707, IRCT20100228003449N28, NCT04350671, NCT04343768, NCT04315948, NCT04492475
Feinstein Institutes for Medical Research at Northwell Health/ Alchem
Pepcid (famotidine), histamine-2 (H2) receptor antagonist
clinical
Phase II study underway in April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04389567, NCT04370262
Fulcrum Therapeutics
losmapimod, oral selective p38 mitogen activated protein kinase inhibitor
clinical
Phase III trial to begin June 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Multiple indications, including facioscapulohumeral muscular dystrophy
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Genentech
MSTT1041A (anti-ST2, the receptor for IL-33)
clinical
Unknown
n/a
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04386616
Genentech
UTTR1147A (IL-22-Fc)
clinical
Unknown
n/a
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04386616
Genetic Engineering and Biotechnology Center (CIGB), Cuba
CIGB-258, immunoregulatory peptide
clinical
Unknown
n/a
Funder
Funder
n/a
Ministry of Public Health of Cuba
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
https://rpcec.sld.cu/ensayos/RPCEC00000313-Sp
Global research sponsors
TD139, specific inhibitor of galectin-3, inhalation powder
clinical
Unknown
n/a
Funder
Funder
n/a
Life Arc (University of Edinburgh)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001736-95 (ACCORD Trial), NCT04473053, ISRCTN14212905
Heron Therapeutics
Cinvanti (aprepitant), a substance P/neurokinin-1 receptor antagonist
clinical
Phase II trial recruiting July 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04470622
Immunic, Inc./ University Hospitals Coventry and Warwickshire NHS Trust
IMU-838, selective oral dihydroorotate dehydrogenase (DHODH) inhibitor
clinical
Phase II trial started June 2020, top line results expected in 2020, Recruiting Aug 2020 (IMU 838 +Oseltamivir)
n/a
Funder
Funder
n/a
University Hospitals Coventry and Warwickshire NHS Trust
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Ulcerative colitis; remitting multiple sclerosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04516915, EudraCT 2020-001805-21
ImmunityBio/ NantKwest
N-803, IL-15 "superagonist" (Nogapendekin alfa inbakicept)
clinical
Phase Ib trial to start June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Bladder Carcinoma In Situ
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04385849
Innovation Pharmaceuticals
Brilacidin, a defensin mimetic
clinical
Phase II trial anticipated to start Q4 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Oral Mucositis; Ulcerative Proctitis/Ulcerative Proctosigmoiditis; Acute Bacterial Skin and Skin Structure Infection
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Inotrem
Nangibotide
clinical
Phaes II trial cleared by FDA, French and Belgian authorities July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Septic shock
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04429334
Insmed Inc.
brensocatib, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1)
clinical
Phase III trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Bronchiectasis and other inflammatory diseases
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001643-13, ISRCTN30564012
Institut National de la Sante et de la Recherche Medicale (Merck KGaA); IRCCS San Raffaele; WHO global SOLIDARITY Trial
Rebif (interferon beta-1a)
clinical
Phase III trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-000936-23, NCT04315948, 2020-001366-11 (Solidarity Spain), NCT04350671, NCT04449380, 2020-002060-31 (Solidarity Chech Republic), EudraCT 2015-002340-14 (REMAP-CAP), NCT04460547, EudraCT 2020-001549-38 (Solidarity Germany)
KD Pharma / SLA Pharma
EPAspire, oral formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Familial adenomatous polyposis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Karyopharm Therapeutics
Xpovio (selinexor), oral, selective inhibitor of nuclear export (SINE) compound
clinical
Phase II trial ongoing July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treat various cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04355676, NCT04349098, EudraCT 2020-001411-25, NCT04534725
King's College London
Flarin (lipid ibuprofen)
clinical
Phase IV trial recruiting in July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04334629
Kintor/ Applied Biology
proxalutamide (GT0918), anti-androgen
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04446429
Laurent Pharmaceuticals
LAU-7b (fenretinide)
clinical
Phase II trial recruiting July 2020, FDA approval to start enrollment August 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treat exaggerated inflammatory response in adult cystic fibrosis patients
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04417257
Massachusetts General Hospital; University of British Columbia; Sanotize Research and Development
Nitric oxide
clinical
Massachusetts General Hospital Phase II trial ongoing July 2020; other Phase II trials recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04305457, NCT04312243, NCT04306393, NCT03331445, NCT04443868, NCT04337918, NCT04456088, NCT04421508, NCT04383002, NCT04388683, NCT04338828, EudraCT 2020-001490-68, EudraCT 2020-001329-30, NCT04460183, NCT04443868, NCT04306393, NCT04476992
MediciNova/ Yale
MN-166 (ibudilast), orally bioavailable, small molecule macrophase migration inhibitory factor (MIF) inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor
clinical
Phase II trial FDA approved and not yet recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of numerous neurodegenerative diseases and substance dependence
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04429555
MedinCell/ University of Utah/ Surgisphere Corp; University of Baghdad; Tanta University; other global research sponsors
ivermectin
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04343092, NCT04345419, NCT04351347, NCT04407507, NCT04392713, NCT04425707, NCT04438850, NCT04405843, NCT04429711, NCT04374279, NCT04360356, NCT04381884, NCT04447235, NCT04435587, NCT04434144, NCT04445311, EudraCT 2020-001474-29, EudraCT 2020-002091-12, EudraCT 2020-001994-66, NCT04460547, NCT04431466, NCT04446104, NCT04446429, NCT04472585, ISRCTN40302986, EudraCT 2020-001971-33, NCT04482686
Multiple global research sponsors
Cozaar (losartan), angiotensin II receptor blocker (ARB)
clinical
Gates Foundation trial results expected by end of summer 2020
n/a
Funder
Funder
n/a
COVID-19 Treatment Accelerator
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04312009, NCT04311177, NCT04349410, NCT04335123, NCT04343001, NCT04328012, NCT04340557, NCT04447235, NCT04428268, EudraCT 2020-001766-11, NCT04394117, NCT04467931, ISRCTN48734830, EudraCT 2020-002040-22
Multiple global research sponsors
Diovan (valsartan), angiotensin II receptor blocker (ARB)
clinical
Veterans observational study ongoing July 2020; Phase IV trials recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04335786, NCT04330300, NCT04394117, NCT04467931, EudraCT 2020-001544-26, EudraCT 2020-001431-27
Multiple global research sponsors, including UK SPIKE-1 trial
camostat mesylate, transmembrane protease serine 2 (TMPRSS2) inhibitor, approved in Japan to treat multiple conditions including pancreatitis
clinical
Phase I/II, Phase II, and Phase III trials recruiting in May 2020
n/a
Funder
Funder
n/a
LIfeArc (SPIKE-1 trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04321096, NCT04353284, NCT04338906, NCT04374019, NCT04355052, EudraCT 2020-002233-15, NCT04455815
Multiple global research sponsors, including University of Tokyo/ National Center for Global Health and Medicine/ Ensysce Biosciences/ Institut Pasteur Korea/ Daiichi Sankyo (inhalation formulation)/ University of Edinburgh
nafamostat, approved in Japan to treat pancreatitis and other diseases
clinical
University of Tokyo trial (IV formulation) starts April 2020; Ensysce trial will be with oral formulation
n/a
Funder
Funder
n/a
Life Arc (University of Edinburgh)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04352400, NCT04418128, EudraCT 2020-002230-32, NCT04473053, ISRCTN14212905
Multiple global research sponsors; ACCORD Trial
heparin; low molecular weight heparin (enoxaparin), anticoagulant
clinical
Phase 2/3/4 trials began June 2020; Sept 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04366960, NCT04360824, NCT04359277, NCT04354155, NCT04367831, NCT04345848, NCT04373707, NCT04372589, NCT04362085, NCT04344756, NCT04408235, NCT04406389, NCT04400799, NCT04377997, NCT04393805, NCT04427098, EudraCT 2020-001739-28, EudraCT 2020-001308-40, EudraCT 2020-001709-21, EudraCT 2020-001891-14, EudraCT 2020-001972-13, NCT04444700, NCT04466670, EudraCT 2020-001736-95 (ACCORD Trial), EudraCT 2020-001708-41, EudraCT 2020-001823-15, NCT04485429, NCT04461925, NCT04486508, NCT04511923, NCT04512079, NCT04530578, NCT04508439, NCT04528888, NCT04542408, NCT04545541
NIH ACTIV-4 Antithrombotics/ nonprofit organizations/numerous biopharmaceutical companies
Apixaban (Eliquis) blood thinner, direct oral anticoagulant
clinical
Phase 3 trials for ACTIV-4 Antithrombotics launched Sept 2020
n/a
Funder
Funder
n/a
National Institute of Heart, Lung, and Blood Institute (NHLBI)/U.S. Operation Warp Speed
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04498273
National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial; Nova Scotia Health Authority; Hospital of Prato; University of Colorado (Eli Lilly); TACTIC-R trial
Olumiant (baricitinib), Janus kinase (JAK) inhibitor
clinical
Eli Lilly Phase III trial started June 2020; NIAID trial remdesivir + baricitinib recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04321993, NCT04320277, NCT04340232, NCT04280705, NCT04345289, NCT04346147, NCT04358614, NCT04373044, NCT04438629, NCT04421027, NCT04362943, NCT04393051, NCT04401579, NCT04390464, NCT04399798, NCT04365764, EudraCT 2020-001246-18, EudraCT 2020-001367-88, EudraCT 2020-001517-21, EudraCT 2020-001854-23, EudraCT 2020-001354-22 (TACTIC-R), EudraCT 2020-001321-31, EudraCT 2020-001052-18, ISRCTN11188345
NeoImmune Tech/ NIAID / University of Nebraska Medical Center
NT-I7 (efineptakin alfa), long-acting human IL-7
clinical
Phase I trial cleared by FDA July 2020; Second study for NT-I7 approved by FDA
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treat solid tumors
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NeuroRx/ Relief Therapeutics/ Thomas Jefferson University Hospital/ NYU Langone Health/ Houston Methodist Hospital
Aviptadil, synthetic form of Vasoactive Intestinal Polypeptide (RLF-100)
clinical
Phase II/III trial ongoing July 2020; FDA grants Fast Track Designation June 2020; Expanded access protocols
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Sarcoid, Pulmonary Fibrosis, Bronchospasm, Erectile Dysfunction, and Acute Respiratory Distress Syndrome (ARDS)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04311697, NCT04453839, NCT04360096, NCT04536350
Novartis / Incyte, numerous researchers globally
Jakafi/jakavi (ruxolitinib)
clinical
Novartis/Incyte Phase III trial started April 2020; Expanded access protocols
n/a
Funder
Funder
n/a
LIfeArc (RAVEN trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000029580, NCT04334044, NCT04331665, NCT04337359, NCT04348071, NCT04338958, NCT04348695, NCT04355793, NCT04354714, NCT04377620, NCT04362137, NCT04366232, NCT04361903, NCT04374149, NCT04338958, NCT04359290, NCT04414098, NCT04403243, EudraCT 2020-001754-21, EudraCT 2020-001963-10
Noveome Biotherapeutics/ Singota Solutions
ST266, cell-free biologic made from anti-inflammatory proteins secreted by placental cells
clinical
Phase I/II to start in Q4 2020; Phase I IV trials expected 1st QTR 2021
n/a
Funder
Funder
n/a
Commonwealth of Pennsylvania
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Multiple ophthalmic indications
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Noxopharm
Veyonda (idronoxil)
clinical
Phase I started July 2020; Phase I approved in Austrilia for NOXCOVID-1 trial to begin at clinical sites in Ukraine and Moldova
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Prostate cancer
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04488575
Numerous global sponsors
Recombinant human interferon alpha-1b
clinical
Phase III trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04320238, NCT04251871, NCT04275388
Numerous research sponsors globally
colchicine
clinical
Open-label Greek study results published June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04326790, NCT04328480, NCT04322565, NCT04322682, NCT04392141, NCT04375202, NCT04355143, NCT04360980, NCT04350320, NCT04416334, NCT04403243, NCT04363437, NCT04324463, NCT04367168, EudraCT 2020-001511-25, EudraCT 2020-001258-23, EudraCT 2020-001603-16, EudraCT 2020-001475-33, EudraCT 2020-001689-12, EudraCT 2020-001841-38, EudraCT 2020-001455-40, NCT04472611, NCT04516941, NCT04510038, NCT04527562, NCT04539873
Numerous research sponsors globally
dipyridamole (Persantine), anticoagulant
clinical
Phase II recruiting July 2020; Individual patient expanded access
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04424901, NCT04391179, NCT04410328
Numerous trials with global research sponsors including World Health Organization SOLIDARITY trial; ORCHID trial with National Heart, Lung, and Blood Institute (NHLBI); REMAP-CAP global trial; Novartis; PRINCIPLE trial
Chloroquine/ Hydroxychloroquine, antimalarial
clinical
Brazilian study results released July 2020; Univ. of Minnesota early, mild outpatient trial results released July 2020; Prevention studies continue in Asia; NIH study stopped in June 2020; Novartis discontinues trial due to feasibility of recruitment in June 2020; WHO discontinues hydroxychloquine arm in the SOLIDARITY trial July 2020; FDA revoked the March 28, 2020 Emergency Use Authorization on June 15, 2020; RECOVERY trial prelim results released June 2020, trial arm stopped
n/a
Funder
Funder
n/a
COVID-19 Treatment Accelerator (University of Washington/ NYU trial and Mahidol Oxford Tropical Medicine Research Unit trial); UK Government (University of Oxford RECOVERY trial and PRINCIPLE trial); Life Arc (PIONEER trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Over 50 trials registered at Clinicaltrials.gov, including: NCT04261517, NCT04303507, NCT04303299, NCT04304053, NCT04307693, NCT04316377, NCT04315948, NCT04321993, ECT2020-001113-21, NCT04323527, NCT04333732, NCT04332991, NCT04345419, NCT04341870, NCT04345289, NCT02735707, NCT04351347, NCT04341493, NCT04332094, NCT04349410, NCT04286503, NCT04328012, NCT04346147, NCT04428268, NCT04350671, EudraCT 2020-001303-16, EudraCT 2020-001825-29, EudraCT 2020-00124618, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT 2020-001367-88, EudraCT number: 2020-00132131, EudraCT 2020-001357-52, NCT04434144, EudraCT 2020-001449-38, NCT04460547, NCT04446104, ISRCTN83971151 (Solidarity), EudraCT 2020-001366-11 (Solidarity Spain), EudraCT 2020-000982-18 (Norway Solidarity), NCT04381936 (RECOVERY), NCT04386070, NCT04330690, NCT04321616, EudraCT 2020-001448-24, EudraCT 2020-001723-13, EudraCT 2020-001528-32, NCT04435587, NCT04308668, NCT04376814, NCT04411433, NCT04392973, NCT04359615, NCT04387760, NCT04322123, EudraCT 2020-001605-23, NCT04365764, EudraCT 2020-001971-33
Numerous trials with research sponsors globally; University of Oxford RECOVERY trial; REMAP-CAP global trial; Covis Pharma B.V.
Methylprednisolone/ ciclesonide (Alvesco)/ hydrocortisone/ corticosteroids
clinical
Japan approves dexmethasone as COVID treatment July 2020; RECOVERY trial results released (dexamethasone) June/July 2020; Phase III trial to begin July 2020
n/a
Funder
Funder
n/a
UK Government (University of Oxford RECOVERY trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04244591, NCT04263402, NCT04273321, ChiCTR2000029656, ChiCTR2000029386, NCT02735707, NCT04330586, 2020-001113-21, NCT04345445, NCT04349410, NCT04329650, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT 2020-001854-23, EudraCT 2020-001413-20, NCT04381936 (RECOVERY), NCT04485429, NCT04461925, NCT04452565, NCT04484493
OncoImmune
CD24Fc, biological immunomodulator (nonpolymorphic regions of CD24 attached to the Fc region of human IgG1)
clinical
Phase III trial progress report released in June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Graft versus Host Disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04317040
Organicell Regenerative Medicine
Organicell Flow, acellular product derived from amniotic fluid
clinical
Phase I/II trial cleared by FDA in May 2020; Individual expanded access results released May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04384445
Orpheris (Ashvattha Therapeutics)
OP-101, dendrimer-based therapy
clinical
FDA agreed to Phase II June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04458298
PTC Therapeutics
PTC299, oral small molecule inhibitor of dihydroorotate dehydrogenase (DHODH)
clinical
Phase 2/3 trial to start in June 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various oncology indications
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04439071
Panoptes Pharma GmbH
PP-001
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Severe eye diseases
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Partner Therapeutics/ Singapore General Hospital/ University Hospital, Ghent
Leukine (sargramostim, rhu-Granulocyte macrophage colony stimulating factor )
clinical
Phase II and Phase IV trials recruiting July 2020, enrollment for Phase II began August 2020
n/a
Funder
Funder
n/a
Other Transaction Agreement (OTA) with Department of Defense (DoD)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pulmonary conditions that affect alveolar macrophases (nebulized leukine); ARDS (IV leukine)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04326920, NCT04400929, NCT04411680, EudraCT 2020-001254-22, NCT04411680
Pfizer; other global research sponsors
Xeljanz (tofacitinib), Janus kinase (JAK) inhibitor
clinical
Pfizer and other Phase II trial not yet recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04332042, NCT04415151, NCT04390061, NCT04412252, NCT04469114, EudraCT 2020-001357-52, EudraCT 2020-002035-30
PharmaMar/ Boryung Pharmaceutical/ Hospitals in Spain
Aplidin (plitidepsin), approved in Australia to treat multiple myeloma
clinical
Phase I trial recruiting July 2020; Trials in Korea to start 3Q 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04382066
Pharming
Ruconest (recombinant human C1 esterase inhibitor)
clinical
Phase II trial not yet recruiting July 2020; compassionate use; 2nd Phase II open label trial to start Sept 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04414631, NCT04530136
PhaseBio
PB1046, long-acting, sustained release human vasoactive intestinal peptide (VIP) analogue
clinical
Phase II trial started July 2020 and results in Q4 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pulmonary arterial hypertension
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04433546
Pulmotect
PUL-042 inhalation solution
clinical
Phase II trials recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Prevent and treat respiratory complications in immunosuppressed cancer patients
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04312997, NCT04313023
RECOVERY trial and multiple global research sponsors
azithromycin, antibiotic
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Over 100 clinical trials registered at clinicaltrials.gov; EudraCT 2020-001303-16, EudraCT 2020-001246-18, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT 2020-001449-38, NCT04446429, EudraCT 2020-001723-13, EudraCT 2020-001113-21 (RECOVERY Trial), NCT04381936 (RECOVERY), NCT04411433, EudraCT 2020-001605-23, EudraCT 2020-001971-33, NCT04461925, NCT04321278
REMAP-CAP trial
Levaquin (levofloxacin), a fluoroquinolone antibacterial
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2015-002340-14 (REMAP-CAP), NCT02735707 (REMAP-CAP)
REMAP-CAP trial
ceftriaxone, broad-spectrum cephalosporin antibiotic
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2015-002340-14 (REMAP-CAP), NCT02735707 (REMAP-CAP)
RedHill Biopharma
Yeliva (opaganib, ABC294640), oral sphingosine kinase-2 (SK2) selective inhibitor
clinical
Phase II/III trials in Russia and UK to start in July 2020; Phase IIa in US ongoing in July 2020; Preliminary data from individual patient expanded access released in April 2020; ; Phase II/III approved for trials in Mexico, UK, Italy, and Russia
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various oncology indications
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04435106, NCT04414618, NCT04467840, EudraCT 2020-002677-95
RedHill Biopharma/ NIAID
RHB-107 (upamostat, WX-671), serine protease inhibitor
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various oncology indications
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Resverlogix
apabetalone (RVX-208), selective BET (bromodomain and extra-terminal) inhibitor
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treat various conditions
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Romark Laboratories; various researchers globally
nitazoxanide, antiprotozoal
clinical
Phase II/III and Phase III trials recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04351347, NCT04348409, NCT04343248, NCT04341493, NCT04345419, NCT04435314, NCT04441398, NCT04463264, NCT04459286, NCT04486313, NCT04423861, NCT04392427, NCT04406246, NCT04382846
SciTech Development, LLC
ST-001 nanoFenretinide (fenretinide)
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
non-Hodgkin's lymphoma
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sun Pharmaceutical Industries Ltd
AQCH, plant-derived (phytopharmaeutical) drug
clinical
Phase II trial started June 2020, results expected by October
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Swedish Orphan Biovitrum/ REMAP-CAP global trial/ Numerous global trial sponsors
Kineret (anakinra), interleukin-1 receptor antagonist
clinical
Some trial results released June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04324021, NCT02735707, NCT04339712, NCT04330638, NCT04366232, NCT04443881, NCT04462757, EudraCT 2020-001636-95, EudraCT 2020-001825-29, EudraCT 2020-001734-36, EudraCT 2020-001466-11, EudraCT 2020-001754-21, EudraCT 2020-001963-10, EudraCT 2020-001739-28, EudraCT 2020-001500-41, EudraCT 2020-001246-18, EudraCT 2020-001039-29, EudraCT 2015-002340-14 (REMAP-CAP)
Synairgen/ University of Southampton
SNG001, inhaled formulation of interferon beta-1a
clinical
Phase II trial initial results released July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Asthma patients with cold or flu infection; COPD patients with viral infections
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04385095
Union Therapeutics/ Institute Pasteur Korea/ Daewoong Therapeutics; First Wave Bio/ANA Therapeutics
UNI9011 (Union Therapeutics), FW-1022 (First Wave Bio), DWRX2003 (Daewoong) niclosamide
clinical
Danish Medicines Agency approved a Phase I trial July 2020 (UN9011, Union Therapeutics); Daewoong to apply for Phase I trial in Korea in July 2020; FDA cleared to begin clinical trials in Aug 2020; Dosing completed in Aug 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Atopic Dermatitis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04345419, NCT04399356, NCT04436458, EudraCT 2020-002233-15
University of Alabama at Birmingham; Leading Biosciences
Lysteda/Cyklokapron/LB1148 (tranexamic acid), an antifibrinolytic
clinical
Phase II recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04338074, NCT04338126, NCT04390217, NCT04550338
University of British Columbia/Apeiron Biologics
APN01; recombinant soluble human Angiotensin Converting Enzyme 2
clinical
Phase II trial recruiting July 2020
n/a
Funder
Funder
n/a
Austrian Government
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute lung injury, Acute respiratory distress syndrome, Pulmonary arterial hypertension
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04335136, EudraCT 2020-001172-15
University of Hawaii (Boehringer Ingelheim); other global research sponsors
Micardis (telmisartan)
clinical
Phase II Univ. of Hawaii trial started June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04360551, NCT04355936, NCT04359953, EudraCT 2020-001303-16, EudraCT 2020-001435-27, NCT04394117, NCT04466241, NCT04356495, NCT04467931, NCT04510662
Vanda Pharmaceuticals / Feinstein Institutes for Medical Research at Northwell Health
tradipitant, a neurokinin-1 receptor antagonist
clinical
Phase III trial started in April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Gastroparesis, motion sickness, and atopic dermatitis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04326426
Various global research sponsors
Aldactone (spironolactone), aldosterone antagonist
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001766-11, NCT04424134, NCT04345887
Various researchers globally, including University of Oxford
almitrine
clinical
Unknown
n/a
Funder
Funder
n/a
LifeArc (University of Oxford trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various lung diseases including Acute Respiratory Distress Syndrome (ARDS)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04357457, NCT04380727
Various researchers worldwide, including Ashford and St Peters Hospital NHS Trust/ Guangdong Uni-Innovation Pharmaceuticals Co., Ltd./ Clear Creek Bio, LLC/BMS
leflunomide, pyrimidine synthesis inhibitor; Dihydroorotate dehydrogenase inhibitor (DHODH- Brequinar)
clinical
FDA IND application accepted for Phase 1a/2 open label safety trials began in summer 2020
n/a
Funder
Funder
n/a
Life Arc (Ashford and St Peters Hospital NHS Trust/ Guangdong Uni-Innovation Pharmaceuticals Co., Ltd. trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04361214
Various researchers worldwide, including University College London/ The Francis Crick Institute (COVASE study)/ I-SPY COVID trial
Pulmozyme (nebulised dornase alfa), a recombinant DNase enzyme
clinical
Phase III trials recruiting June 2020
n/a
Funder
Funder
n/a
Life Arc (COVASE study)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04409925, NCT04359654, NCT04387786, NCT04355364, NCT04402944, NCT04402970
Vicore Pharma
VP01, Angiotensin II Type 2 receptor activator
clinical
Phase II dosing began of ATTRACT study in India
n/a
Funder
Funder
n/a
Life Arc
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pulmonary fibrosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ViralClear Pharmaceuticals
merimepodib, IMPDH inhibitor
clinical
Phase II trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Chronic Hepatitis C; Psoriasis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04410354
Washington University School of Medicine in St. Louis
Luvox (fluvoxamine), a selective serotonin reuptake inhibitor
clinical
Phase II trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04342663
Zydus Cadila Group; The Camelot Foundation
interferon/peginterferon alpha-2b, PegIntron, Sylatron, IntronA, PegiHep
clinical
Phase II/III enrolling May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04273763, NCT04349410, NCT04379518
Zydus Cadila/ Avant Sante Research Center
desidustat, a hypoxia inducible factor prolyl hydroxylase inhibitor
clinical
Phase IIb trials approved to start in Mexico July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Chronic Kidney Disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
aTyr
ATYR1923, fusion protein (immuno-modulatory domain of histidyl tRNA synthetase fused to the Fc region of a human antibody) modulator of neuropilin-2
clinical
Phase II study started in June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pulmonary sarcoidosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04412668
BioIncept
sPIF (synthetic pre implantation factor)
pre-clinical
Preparing for a Phase I/IIa trial in May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Bioxytran
BXT-25; glycoprotein
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CEL-SCI / University of Georgia Center for Vaccines and Immunology
LEAPS COVID 19 conjugate; Peptides targeting the NP protein
pre-clinical
Animal study results released July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chelation Partners
DIBI, iron-binding polymer
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Hebrew University of Jerusalem/ University of Pennsylvania/ University Arizona
Tricor (fenofibrate), peroxisome proliferator-activated receptor (PPAR) alpha agonist
pre-clinical
Invite only intervention trial Sept 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04517396
Lupa Bio, Inc.
New drug based on a sugar found in human milk
pre-clinical
Plans to sumit an IND in 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Merck KGaA
M5049, small molecule that block the activation of Toll-like receptor (TLR)7 and TLR8
pre-clinical
FDA cleared Phase II trial to begin in June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various immuology indications
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04448756
Merck/ IRBM
Peptides
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Moleculin Biotech/ University of Texas Medical Branch/ Sterling Pharma USA
WP1122, glucose decoy prodrug (and related drug candidates)
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NanoViricides/ TheraCour Pharma Inc.
A number of synthesized nanoviricide drug candidates
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Institute of Allergy and Infectious Disease (NIAID)
Adaptive COVID-19 Treatment Trial 3 (ACTT-3), Remdesivir + interferon beta-1a
pre-clinical
Phase III trial started August 2020
n/a
Funder
Funder
n/a
National Institute of Allergy and Infectious Diseases (NIAID)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04492475
Nocion Therapeutics
Nocions, molecules that either selectively block Nav 1.7 or antagonize large-pore channels
pre-clinical
Phase I trial to start July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Persephone Biosciences
Microbiome therapeutic
pre-clinical
Clinical trials to start in 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Pneumagen Ltd.
Neumifil, multivalent carbohydrate binding molecules
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Quotient Sciences/ CytoAgents
GP1681, small molecule inhibitor of cytokine release
pre-clinical
Phase I/II to start in 2020
n/a
Funder
Funder
n/a
Richard King Mellon Foundation
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Silkim Pharma
Coronzot, a novel family of drugs, sequestration of the labile iron
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
pHbarrier
pH barrier, transepithelial nebulized alkaline treatment
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
A successful vaccine would be able to protect the population from COVID-19. Developers from around the world are using different platforms, from tested ways to induce immunity in a vaccinated person (e.g., live attenuated virus vaccines), to innovative platforms never used before (e.g., DNA-based vaccines), to build vaccines to protect people against COVID-19 disease. Each type offers unique benefits and challenges and we will likely need more than one approved vaccine to vaccinate every person around the globe.
Zydus Cadila Healthcare Limited
DNA; (ZyCoV-D) plasmid vaccine
stage-1half2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II study: Phase I began July 2020 and Phase II began August 2020, initial results expected September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/07/026352
Osaka University/ AnGes/ Takara Bio/ Cytiva/ Brickell Biotech
DNA; (AG0301 & AG0302) plasmid vaccine + adjuvant
stage-1half2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began end of June 2020, results expected during Q1 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04463472, NCT04527081
Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and Technology (POSTECH)/ Binex/ PT Kalbe Pharma
DNA; (GX-19)
stage-1half2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II study: Phase I began end of June 2020, preliminary data expected September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04445389
Inovio Pharmaceuticals/ Beijing Advaccine Biotechnology/ VGXI Inc./ Richter-Helm BioLogics/ Ology Bioservices/ International Vaccine Institute/ Seoul National University Hospital/ Thermo Fisher Scientific
DNA; (INO-4800) plasmid vaccine with electroporation
stage-1half2
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense
Related use
Related use
n/a
Same platform as multiple vaccine candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III trial expected to begin summer 2020; Phase I/IIa trial began July 2020; Animal study results released July 2020; Joined US Operation Warp Speed in June 2020; Phase I began April 2020, interim data of ongoing study released June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04336410, NCT04447781
Statens Serum Institute, Denmark
DNA; (CoVAXIX) plasmid vaccine
pre-clinical
Funder
Funder
n/a
Statens Serum Institute, Denmark
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I is expected to start in late 2020 or early 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Symvivo
DNA; bacTRL-Spike
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04334980
Scancell/ University of Nottingham/ Nottingham Trent University
DNA; plasmid vaccine RBD&N
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start in Q1 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Entos Pharmaceuticals/ Cytiva
DNA; (Covigenix)
pre-clinical
Funder
Funder
n/a
Canadian Institutes of Health Research (CIHR)/ Research Nova Scotia (RNS)/ Institute for Ageing (IA)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II expected to begin in late July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Mediphage Bioceuticals/ University of Waterloo/ Lambton College
DNA; msDNA-VLP
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BioNet Asia/ Technovalia/ Vax4COVID/ The University of Sydney/ The University of Western Australia/ Telethon Kids Institute
DNA; (COVIGEN) needle-free delivery
pre-clinical
Funder
Funder
n/a
Australian Government Medical Research Future Fund (MRFF)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/Ib expected to begin September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Immunomic Therapeutics/ EpiVax/ PharmaJet
DNA; plasmid vaccine, needle-free delivery
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chula Vaccine Research Center
DNA with electroporation
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
OPENCORONA Project: Karolinska Institute/ Justus Liebig University Giessen/ Public Health Agency of Sweden (FoHM)/ IGEA/ Cobra Biologics/ Adlego Biomedical/ Region Stockholm
DNA with electroporation
pre-clinical
Funder
Funder
n/a
European Commission (Horizon 2020 Program)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin in 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Research Centre, Egypt
DNA; plasmid vaccine S, S1, S2, RBD & N
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Takis/ Applied DNA Sciences/ Evvivax
DNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical results released in May and July 2020; Phase I expected to begin fall 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Ege University Drug Development and Pharmacokinetic Research Application Center (ARGEFAR)/ Scientific and Technological Research Council of Turkey (TUBITAK)
DNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Cambridge/ DIOSynVax
DNA; (DIOS-CoVax2) synthetic gene inserts compatible with multiple delivery systems
pre-clinical
Funder
Funder
n/a
Innovate UK
Related use
Related use
n/a
Influenza, Ebola
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin late fall 2020 or early 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer/ Researcher
Product Description
Phase
PRE
I
II
III
RR
IV
Sinovac/ Instituto Butantan/ Bio Farma
Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc)
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
Received approval for Phase I/II trial in adolescents and children in September 2020; Phase III trial began end of July 2020; Phase II began June 2020, mid-phase II results released August 2020; Preliminary results from Phase I/II trials released June and September 2020 (aged 60+) 2020; Received early approval for emergency use in China in August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04352608, NCT04383574, NCT04456595, NCT04508075, NCT04551547, 669/UN6.KEP/EC/2020
Wuhan Institute of Biological Products/ Sinopharm
Inactivated
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III trial began July 2020; Phase I/II early trial results released June 2020, Phase I/II interim analysis published August 2020; Received early approval for emergency use in the UAE in September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000031809, ChiCTR2000034780
Beijing Institute of Biological Products/ Sinopharm
Inactivated
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III trial began July 2020; Received early approval for emergency use in the UAE in September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000032459, ChiCTR2000034780
Institute of Medical Biology, Chinese Academy of Medical Sciences
Inactivated
stage-2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II began June 2020; Phase I began May 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04412538, NCT04470609
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology
Inactivated; whole-virion (COVAXIN) (BBV152)
stage-1half2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III expected to begin mid-October 2020; Phase I/II study: Phase I began July 2020 and Phase II began September 2020, initial results expected September 2020; Animal study results released September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/07/026300, NCT04471519
Research Institute for Biological Safety Problems, Republic of Kazakhstan
Inactivated, QAZCOVID-IN®
stage-1half2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04530357
Sinovac/ Dynavax
Inactivated + adjuvant (CpG 1018)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Erciyes University
Inactivated
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Selcuk University
Inactivated
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Valneva/ Dynavax
Inactivated (Inactivated + CpG 1018), VLA2001
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Japanese Encephalitis
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
KM Biologics
Inactivated (inactivated + alum)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for JE, Zika
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Osaka University / BIKEN / NIBIOHN
Inactivated
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Beijing Minhai Biotechnology Co., Ltd.
Inactivated
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Research Centre, Egypt
Inactivated whole virus
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer/ Researcher
Product Description
Phase
PRE
I
II
III
RR
IV
Indian Immunologicals Ltd/ Griffith University
Codon deoptimized live attenuated virus
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Meissa Vaccines 
MV-014-210
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for RSV
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase 1 beginning of 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Mehmet Ali Aydinlar University/ Acıbadem Labmed Health Services A.S.
Codon deoptimized live attenuated vaccines
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Codagenix / Serum Institute of India
Codon deoptimized live attenuated virus
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal data in summer 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer/ Researcher
Product Description
Phase
PRE
I
II
III
RR
IV
CanSino Biologics/Beijing Institute of Biotechnology/ Canada's National Research Council/ / Petrovax
Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV)
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for EBOV
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III dosed September 2020; Phase II began April 2020, initial results released May 2020, mid-phase results released July 2020; Received early approval for military use in China in June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04313127, ChiCTR2000030906, ChiCTR2000031781, NCT04398147, NCT04341389, NCT04526990, NCT04540419
Gamaleya Research Institute
Adeno-based, Gam-COVID-Vac Lyo (Sputnik V)
stage-3
Funder
Funder
n/a
Russian Direct Investment Fund (RDIF)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III (post-registration) trial began September 2020; Phase I/2 began June 2020, results published September 2020; Received early approval for use in Russia in August 2020, Mass production expected to begin September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04437875, NCT04436471, NCT04530396
University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA
Non-replicating viral vector; AZD 1222 (formerly ChAdOx1)
stage-3
Funder
Funder
n/a
Coalition for Epidemic Preparedness Innovations (CEPI)/ UK Government/ Biomedical Advanced Research and Development Authority (BARDA)/ Gavi, the Vaccine Alliance
Related use
Related use
n/a
Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague
Anticipated Next Steps
Anticipated Next Steps
n/a
Study protocol for late-stage clinical trials released September 2020; AstraZeneca clinical trials resumed in the UK on 9/14/2020 and in Brazil and South Africa on 9/15/2020, AstraZeneca voluntarily paused vaccination to allow independent review of safety data on 9/8/2020; Phase III trial began Jun 2020 and expanded into US in Aug 2020; Phase II/III began May 2020; Interim results from Phase I/II trial released Jul 2020; Selected for US Operation Warp Speed in May 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001072-15, EudraCT 2020-001228-32, ISRCTN89951424, NCT04324606, NCT04400838, NCT04444674, NCT04516746, PACTR202005681895696, PACTR202006922165132
Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent BioSolutions/ Catalent/ Biological E
Ad26.COV2-S, Non replicating viral vector; Ad26 (alone or with MVA boost)
stage-1half2
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola, HIV, RSV
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III trial expected to begin in September 2020; Phase I/IIa began end of July 2020; Animal study results published July and September 2020; Selected for US Operation Warp Speed in February 2020 and awarded funding in August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04436276, NCT04505722
ReiThera/ Leukocare/ Univercells/ National Institute of Infectious diseases Lazzaro Spallanzani
Non-replicating viral vector; replication defective simian adenovirus encoding SARS-CoV-2 S (GRAd-CoV2)
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began August 2020; Phase II/III trial expected to begin by the end of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-002835-31, NCT04528641
Vaxart/ Emergent BioSolutions
Non-replicating viral vector; Oral Vaccine platform
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE
Anticipated Next Steps
Anticipated Next Steps
n/a
FDA clearance for Phase I trial received September 2020, recruiment expected to begin September 2020; Pre-clinical results released September 2020; Data from ongoing animal challenge study expected in October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Stabilitech Biopharma Ltd
Oral Ad5 S
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO, Thailand
Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Bharat Biotech/ Thomas Jefferson University
Recombinant deactivated rabies virus containing S1
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Ankara University
Adenovirus-based
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
GeoVax / BravoVax
Non-replicating viral vector; MVA encoded VLP
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for LASV, EBOV, MARV, HIV
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Altimmune / University of Alabama at Birmingham
AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I trial to begin Q3 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
DZIF - German Center for Infection Research/ IDT Biologika GmbH
Non-replicating viral vector; MVA-S encoded
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for many pathogens
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Valo Therapeutics Ltd
Adenovirus-based + HLA-matched peptides (Pan-Corona)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Institut Pasteur/ TheraVectys
Intranasal lentiviral vector vaccine
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal study results released July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ImmunityBio/ NantKwest
Non-replicating viral vector; [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for flu, Chik, Zika, EBOV, LASV, HIV/SIV, cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal study results released August 2020; Selected for US Operation Warp Speed in May 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Manitoba
Non-replicating viral vector; dendritic cell-based vaccine
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IDIBAPS- Hospital Clinic, Spain
MVA-S
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Greffex
Non-replicating viral vector; Ad5 S (GREVAX™ platform)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Centro Nacional Biotecnologia (CNB-CSIC), Spain
Non-replicating viral vector, MVA expressing structural proteins
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ID Pharma
Sendai virus vector
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Research Centre, Egypt
Influenza A H1N1 vector
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Georgia/ University of Iowa
Non-replicating viral vector; parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Erciyes University
Adeno5-based
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Grousbeck Gene Therapy Center at Mass. Eye and Ear/ AveXis, a Novartis Company/ Viralgen/ Aldevron/ Catalent/ Penn Medicine
AAVCOVID, Adeno-associated viral vector (AAV), spike protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase 1 to begin second half of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer/ Researcher
Product Description
Phase
PRE
I
II
III
RR
IV
Novavax/Emergent Biosolutions/ Praha Vaccines/ Biofabri/ Fujifilm Diosynth Biotechnologies/ FDB/ Serum Institute of India/ SK bioscience/ Takeda Pharmaceutical Company Limited/ AGC Biologics/ PolyPeptide Group
Protein subunit; Full-length recombinant SARS COV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M (NVX-CoV2373)
stage-2
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)/ US Department of Defense/ Gates Foundation
Related use
Related use
n/a
Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III trial expected to begin fall 2020; Phase IIb trial began Aug 2020; Selected for US Operation Warp Speed July 2020; Phase I/II began end of May 2020; Animal study & preliminary Phase I results released Aug 2020, Phase I results published Sept 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04368988, NCT04533399
Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences
Adjuvanted recombinant protein (RBD-Dimer)
stage-2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II began July 2020; Received approval to launch clinical trials in China in June 2020; Phase I preliminary results expected in September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04445194, NCT04466085
Sanofi Pasteur/ GSK
Protein subunit; S protein, baculovirus production
stage-1half2
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Health and Human Services (HHS)/ US Department of Defense (DoD)
Related use
Related use
n/a
Same platform as vaccine candidates for Influenza, SARS-CoV (FDA approved vaccine)
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began September 2020; Selected for US Operation Warp Speed in April 2020 and awarded funding in July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04537208
Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology "VECTOR"
Peptide vaccine, EpiVacCorona
stage-1half2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II trial began end of July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04527575
Instituto Finlay de Vacunas
RBD + Adjuvant (FINLAY-FR-1)
stage-1half2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
RPCEC00000332
University of Queensland/CSL/Seqirus
Protein subunit; molecular clamp stabilized Spike protein with MF59 adjuvant
stage-1
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)/Queensland Government/Federal Government (Australia)/Paul Ramsay Foundation
Related use
Related use
n/a
Same platform as vaccine candidates for Nipah, influenza, Ebola, Lassa
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I trial began July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ACTRN12620000674932p, NCT04495933
West China Hospital, Sichuan University
RBD (baculovirus production expressed in Sf9 cells)
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began end of August 2020; Animal study data published July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000037518
Clover Biopharmaceuticals Inc./ GSK/ Dynavax
Protein subunit, native like trimeric subunit spike protein
stage-1
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, RSV, Influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
CEPI partnership expanded in July 2020, Phase I trial started June 2020, preliminary results expected August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04405908
Adimmune Corporation
Baculovirus-insect cells expression system, spike (S) protein (tAdimrSC-2f)
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began end of August 2020; Phase II expected to begin November 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04522089
Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma/ Oxford Expression Technologies
Protein subunit; recombinant spike protein with Advax adjuvant (COVAX-19)
stage-1
Funder
Funder
n/a
Innovate UK
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I trial began July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04453852
University Hospital Tuebingen
SARS-CoV-2 HLA-DR peptides
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04546841
Medigen Vaccine Biologics Corp/ NIAID/ Dynavax
MVC-COV1901 vaccine injection; S-2 P protein + CpG 1018
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin September 2020; Animal study data released August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04487210
AnyGo Technology
Protein subunit, recombinant S1-Fc fusion protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Izmir Biomedicine and Genome Center
Recombinant S protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
iBio / CC-Pharming
Protein subunit; Subunit protein, plant produced
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BiOMVis Srl/ University of Trento
OMV-based vaccine
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing
Protein subunit (gp-96 backbone)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal data released August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
MOGAM Institute for Biomedical Research, GC Pharma
Protein subunit
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
LakePharma, Inc.
Protein subunit, nanoparticle vaccine
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
St. Petersburg Scientific Research Institute of Vaccines and Serums
Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Baiya Phytopharm/ Chula Vaccine Research Center
Plant-based subunit (RBD-Fc + Adjuvant)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ImmunoPrecise/ LiteVax BV
Spike-based (epitope screening)
pre-clinical
Funder
Funder
n/a
TRANSVAC2
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Lomonosov Moscow State University
Structurally modified spherical particles of the tobacco mosaic virus (TMV)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Research Centre, Egypt
Protein Subunit S, N, M & S1 protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EpiVax / University of Georgia
Protein subunit; S protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Inf H7N9
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Intravacc/Epivax
Outer Membrane Vesicle (OMV)-subunit
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Research Institute for Biological Safety Problems, Rep of Kazakhstan
Protein subunit
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Baylor College of Medicine
Protein subunit; S1 or RBD protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Alberta
Protein subunit; spike based
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Hepatitis C
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Soligenix/ University of Hawaii at Mānoa
CiVax™ COVID-19 vaccine candidate; spike protein + novel adjuvant
pre-clinical
Funder
Funder
n/a
Soligenix, Inc.
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical testing results released in July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Intravacc/Epivax
Outer Membrane Vesicle (OMV)-peptide
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Neovii/Tel Aviv University
RBD-based
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of California, San Diego
Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch
pre-clinical
Funder
Funder
n/a
National Science Foundation (Rapid Response Research [RAPID] grant)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Institute of Infectious Disease, Japan
Protein subunit, S protein + adjuvant
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan
Protein subunit, VLP-recombinant protein + adjuvant
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Kentucky BioProcessing (British American Tobacco)
RBD-based
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II expected to begin August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04473690
InnoMedica
Protein subunit, TaliCoVax19
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH)
RBD protein (baculovirus production) + FAR-Squalene adjuvant
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria
Subunit
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Pittsburgh
PittCoVacc, Protein subunit, microneedle arrays S1 subunit
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start as early as June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
OncoGen
Protein subunit, synthetic long peptide vaccine candidate for S and M proteins
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Innovax / Xiamen University / GSK
Protein subunit; COVID-19 XWG-03 truncated Spike proteins
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HPV
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Biological E Ltd
Protein subunit; adjuvanted protein subunit (RBD)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Applied Biotechnology Institute, Inc.
Orally delivered, heat stable subunit
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
WRAIR / USAMRIID
Protein subunit; S protein
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
MIGAL Galilee Research Institute
Protein subunit; oral E. coli-based protein expression system of S and N proteins
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Virginia
S subunit intranasal liposomal formulation with GLA/3M052 adjs.
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of San Martin and CONICET, Argentina
Protein subunit
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
PDS Biotechnology
PDS-0203; Versamune T-cell activating technology
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccines against cancers, HBV, influenza, and tuberculosis
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Max-Planck Institute of Colloids and Interfaces
Targeted (Langerhans cell specific) protein subunit; spike based
pre-clinical
Funder
Funder
n/a
KHAN-1 Technology Transfer Fund I GmbH & Co KG
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
VIDO-InterVac, University of Saskatchewan
Protein subunit, adjuvanted microsphere peptide
pre-clinical
Funder
Funder
n/a
The Government of Saskatchewan and the Canadian Federal Government
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal testing results expected in April 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Quadram Institute Biosciences
OMV-based vaccine
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Flu A, plaque
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ExpreS2ion
Protein subunit, drosophila S2 insect cell expression system VLPs
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology "VECTOR"
Subunit vaccine
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Generex / EpiVax
Protein subunit; Ii-Key peptide
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, SARS-CoV, Influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada
Protein subunit; DPX-COVID-19, protein subunit, peptide antigens formulated in LNP
pre-clinical
Funder
Funder
n/a
National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), Atlantic Canada Opportunities Agency (ACOA), and Next Generation Manufacturing Canada (NGen)
Related use
Related use
n/a
Same platform as vaccine candidates for cancer and infectious diseases, including malaria and anthrax
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start by Summer 2020, results expected by Fall 2020; Phase II expected to start in the second half of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
PREVENT-nCoV consortium (AdaptVac, Institute for Tropical Medicine at University of Tubingen, Leiden University Medical Center, University of Copenhagen, ExpreS2ion Biotechnologies, Wageningen University)/ Bavarian Nordic
Protein subunit, capsid-like particle (CLP)
pre-clinical
Funder
Funder
n/a
European Commission (Horizon 2020 Program)
Related use
Related use
n/a
Same platform as vaccine candidates for HPV
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to begin by February 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
UMN Pharma (Shionogi)
Protein subunit; recombinant protein vaccine, utilizing baculovirus expression vector system technology
pre-clinical
Funder
Funder
n/a
Japan Agency for Medical Research and Development
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start by end of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a